Guo Yadong, Cai Keke, Mao Shiyu, Zhang Junfeng, Wang Longsheng, Zhang Ziwei, Liu Mengnan, Zhang Wentao, Wu Yuan, Yan Yang, Yao Xudong
Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, People's Republic of China,
Department of Urology, First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.
Cancer Manag Res. 2018 Oct 23;10:4789-4804. doi: 10.2147/CMAR.S180301. eCollection 2018.
Earlier studies have indicated the prognostic value of the pretreatment C-reactive protein (CRP)/albumin ratio (CAR) in multiple tumor types. The present study attempts to investigate the predictive role of preoperative CAR in patients with bladder cancer after radical cystectomy (RC), and explores its prognostic index value.
A total of 131 patients with bladder cancer after RC between 2009 and 2015 were analyzed in the present study. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and Cox regression analyses. Prediction accuracy was evaluated through the area under the receiver operating characteristic curve (AUC).
The median follow-up time for all patients in the present retrospective study was 39.72 months (15.51-53.26 months). The Kaplan-Meier curve analysis indicated that bladder cancer patients with high preoperative CAR (>0.2) were significantly associated with decreased PFS and OS (all, <0.001). The multivariate analysis confirmed CAR as a common independent prognostic factor for PFS and OS. Furthermore, the effective combination of CAR and pathological T staging constituted a new index (CART), and was observed to be an independent risk factor for OS (CART score =2, HR=0.264; 95% CI: 0.106-0.660, =0.004; CART score =3, HR =0.371; 95% CI: 0.208-0.661, =0.001). However, CART did not show any prognostic significance for PFS. Importantly, the AUC values of CAR for OS and PFS were higher than other conventional clinical indices.
The present study demonstrated that CAR can be used as a new prognostic indicator of OS and PFS in patients with bladder cancer after RC. Combining the CAR score with pathological T staging as the CART score appears to be a more effective prognostic indicator of poor OS, but not PFS.
早期研究已表明术前C反应蛋白(CRP)/白蛋白比值(CAR)在多种肿瘤类型中的预后价值。本研究旨在探讨术前CAR在根治性膀胱切除术(RC)后膀胱癌患者中的预测作用,并探索其预后指标价值。
本研究分析了2009年至2015年间131例行RC术后的膀胱癌患者。采用Kaplan-Meier法和Cox回归分析评估总生存期(OS)和无进展生存期(PFS)。通过受试者工作特征曲线(AUC)下面积评估预测准确性。
在本回顾性研究中,所有患者的中位随访时间为39.72个月(15.51 - 53.26个月)。Kaplan-Meier曲线分析表明,术前CAR高(>0.2)的膀胱癌患者与PFS和OS降低显著相关(均P<0.001)。多因素分析证实CAR是PFS和OS的常见独立预后因素。此外,CAR与病理T分期的有效组合构成了一个新指标(CART),并被观察到是OS的独立危险因素(CART评分为2,HR = 0.264;95%CI:0.106 - 0.660,P = 0.004;CART评分为3,HR = 0.371;95%CI:0.208 - 0.661,P = 0.001)。然而,CART对PFS未显示任何预后意义。重要的是,CAR对OS和PFS的AUC值高于其他传统临床指标。
本研究表明,CAR可作为RC术后膀胱癌患者OS和PFS的新预后指标。将CAR评分与病理T分期结合作为CART评分似乎是OS不良的更有效预后指标,但不是PFS的。